Results 11 to 20 of about 16,388 (147)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Медицинский совет, 2021 Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva +2 more
doaj +1 more source
P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
Artery Research, 2017 Purpose/Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are modestly but significantly associated with increased risk of total cardiovascular events.
Losif Koutagiar +7 more
doaj +1 more source
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Journal of Lipid Research, 2008 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey +5 more
doaj +1 more source
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
JACC: Case Reports, 2020 Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with ...
Bruce A. Warden, PharmD +5 more
doaj +1 more source
Perkembangan Implikasi Biologi dan Klinis Proprotein Convertase Subtilisin-Kexin 9
Majalah Kardiologi Indonesia, 2017 Pada tahun 2003 Proprotein Convertase Subtilisin-Kexin 9 (PCSK9) berhasil diidentifikasi.1 PCSK9 berfungsi meningkatkan kadar LDL Cholesterol (LDL-C) melalui degradasi LDL Receptor (LDLR).2 Penemuan PCSK9 telah merevolusi serta merupakan perkembangan ...
doaj +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Neoplasia: An International Journal for Oncology Research, 2012 High circulating cholesterol is associated with hypercholesterolemia, atherosclerosis, and stroke. However, the relation between cholesterol and tumorigenesis/metastasis is controversial.
Xiaowei Sun +5 more
doaj +1 more source
Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions
Journal of Clinical and Preventive Cardiology, 2017 The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus +5 more
doaj +1 more source
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
JACC: Case Reports, 2020 A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD +6 more
doaj +1 more source
Sex difference in circulating PCSK9 and its clinical implications
Frontiers in Pharmacology, 2022 Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs).
Fang Jia +4 more
doaj +1 more source